Clinical Trial Update: A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study of olaratumab (IMC-3G3) in previously treated patients with unresectable and/or metastatic gastrointestinal stromal tumors was terminated; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Status: TERMINATED | Results posted: 2017-01-16